Study wrapper · #893
Beyond weight loss: multisystem benefits of obesity medications.
Savas M, Kuckuck S, Boon MR, et al. The lancet. Diabetes & endocrinology. 2026.
DOI: 10.1016/s2213-8587(26)00100-2PubMed: 42208956
Editor's note
This narrative review of obesity medications covers semaglutide and tirzepatide among many agents, summarizing multisystem benefits reported across RCTs and meta-analyses. Both peptides are genuine subjects but sit within a broad drug-class overview rather than a focused analysis. Useful context, though weight-loss-independent effects are described as accumulating rather than settled.
Plain-language abstract
This review synthesizes trial evidence that obesity medications, including semaglutide and tirzepatide, are associated with benefits across cardiovascular, metabolic, liver, kidney, and other conditions beyond weight loss.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026